메뉴 건너뛰기




Volumn 1, Issue 5, 2016, Pages 301-308

Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012

Author keywords

cardiovascular drug development; regulatory science; translational research

Indexed keywords


EID: 85002638649     PISSN: 2452302X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacbts.2016.03.012     Document Type: Review
Times cited : (32)

References (38)
  • 1
    • 84950104119 scopus 로고    scopus 로고
    • Heart Disease and Stroke Statistics-2016 Update: a report from the American Heart Association
    • 1 Mozaffarian, D., Benjamin, E.J., Go, A.S., et al. Heart Disease and Stroke Statistics-2016 Update: a report from the American Heart Association. Circulation 133 (2016), e38–e360.
    • (2016) Circulation , vol.133 , pp. e38-e360
    • Mozaffarian, D.1    Benjamin, E.J.2    Go, A.S.3
  • 2
    • 84905161219 scopus 로고    scopus 로고
    • Global burden of cardiovascular disease: time to implement feasible strategies and to monitor results
    • 2 Fuster, V., Global burden of cardiovascular disease: time to implement feasible strategies and to monitor results. J Am Coll Cardiol 64 (2014), 520–522.
    • (2014) J Am Coll Cardiol , vol.64 , pp. 520-522
    • Fuster, V.1
  • 3
    • 84940447040 scopus 로고    scopus 로고
    • Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
    • 3 Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386 (2015), 743–800.
    • (2015) Lancet , vol.386 , pp. 743-800
  • 4
    • 2942592213 scopus 로고    scopus 로고
    • Cardiovascular disease in non-Western countries
    • 4 Reddy, K.S., Cardiovascular disease in non-Western countries. N Engl J Med 350 (2004), 2438–2440.
    • (2004) N Engl J Med , vol.350 , pp. 2438-2440
    • Reddy, K.S.1
  • 5
    • 33644878249 scopus 로고    scopus 로고
    • Cardiovascular disease in the developing world and its cost-effective management
    • 5 Gaziano, T.A., Cardiovascular disease in the developing world and its cost-effective management. Circulation 112 (2005), 3547–3553.
    • (2005) Circulation , vol.112 , pp. 3547-3553
    • Gaziano, T.A.1
  • 6
    • 84928036813 scopus 로고    scopus 로고
    • Cardiovascular drug development: is it dead or just hibernating?
    • 6 Fordyce, C.B., Roe, M.T., Ahmad, T., et al. Cardiovascular drug development: is it dead or just hibernating?. J Am Coll Cardiol 65 (2015), 1567–1582.
    • (2015) J Am Coll Cardiol , vol.65 , pp. 1567-1582
    • Fordyce, C.B.1    Roe, M.T.2    Ahmad, T.3
  • 7
    • 62749084498 scopus 로고    scopus 로고
    • An uncertain future for cardiovascular drug development?
    • 7 Garber, A.M., An uncertain future for cardiovascular drug development?. N Engl J Med 360 (2009), 1169–1171.
    • (2009) N Engl J Med , vol.360 , pp. 1169-1171
    • Garber, A.M.1
  • 8
    • 84891142213 scopus 로고    scopus 로고
    • Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial
    • 8 Nicholls, S.J., Kastelein, J.J., Schwartz, G.G., et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA 311 (2014), 252–262.
    • (2014) JAMA , vol.311 , pp. 252-262
    • Nicholls, S.J.1    Kastelein, J.J.2    Schwartz, G.G.3
  • 9
    • 84903532987 scopus 로고    scopus 로고
    • Drug development and FDA approval, 1938-2013
    • 9 Darrow, J.J., Kesselheim, A.S., Drug development and FDA approval, 1938-2013. N Engl J Med, 370, 2014, e39.
    • (2014) N Engl J Med , vol.370 , pp. e39
    • Darrow, J.J.1    Kesselheim, A.S.2
  • 11
    • 84948712481 scopus 로고    scopus 로고
    • Two decades of new drug development for central nervous system disorders
    • 11 Kesselheim, A.S., Hwang, T.J., Franklin, J.M., Two decades of new drug development for central nervous system disorders. Nat Rev Drug Discov 14 (2015), 815–816.
    • (2015) Nat Rev Drug Discov , vol.14 , pp. 815-816
    • Kesselheim, A.S.1    Hwang, T.J.2    Franklin, J.M.3
  • 12
    • 41449104685 scopus 로고    scopus 로고
    • Drug-review deadlines and safety problems
    • 12 Carpenter, D., Zucker, E.J., Avorn, J., Drug-review deadlines and safety problems. N Engl J Med 358 (2008), 1354–1361.
    • (2008) N Engl J Med , vol.358 , pp. 1354-1361
    • Carpenter, D.1    Zucker, E.J.2    Avorn, J.3
  • 13
    • 33645675960 scopus 로고    scopus 로고
    • Estimating the cost of new drug development: is it really 802 million dollars?
    • 13 Adams, C.P., Brantner, V.V., Estimating the cost of new drug development: is it really 802 million dollars?. Health Aff (Millwood) 25 (2006), 420–428.
    • (2006) Health Aff (Millwood) , vol.25 , pp. 420-428
    • Adams, C.P.1    Brantner, V.V.2
  • 14
    • 84893275211 scopus 로고    scopus 로고
    • Regulatory watch: where do new medicines originate from in the EU?
    • 14 Lincker, H., Ziogas, C., Carr, M., Porta, N., Eichler, H.G., Regulatory watch: where do new medicines originate from in the EU?. Nat Rev Drug Discov 13 (2014), 92–93.
    • (2014) Nat Rev Drug Discov , vol.13 , pp. 92-93
    • Lincker, H.1    Ziogas, C.2    Carr, M.3    Porta, N.4    Eichler, H.G.5
  • 15
    • 84958672783 scopus 로고    scopus 로고
    • Vaccine pipeline has grown during the past two decades with more early-stage trials from small and medium-size companies
    • 15 Hwang, T.J., Kesselheim, A.S., Vaccine pipeline has grown during the past two decades with more early-stage trials from small and medium-size companies. Health Aff (Millwood) 35 (2016), 219–226.
    • (2016) Health Aff (Millwood) , vol.35 , pp. 219-226
    • Hwang, T.J.1    Kesselheim, A.S.2
  • 16
    • 84901603869 scopus 로고    scopus 로고
    • Target small firms for antibiotic innovation
    • 16 Hwang, T.J., Carpenter, D., Kesselheim, A.S., Target small firms for antibiotic innovation. Science 344 (2014), 967–969.
    • (2014) Science , vol.344 , pp. 967-969
    • Hwang, T.J.1    Carpenter, D.2    Kesselheim, A.S.3
  • 17
    • 84884271849 scopus 로고    scopus 로고
    • An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011
    • 17 Lanthier, M., Miller, K.L., Nardinelli, C., Woodcock, J., An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011. Health Aff (Millwood) 32 (2013), 1433–1439.
    • (2013) Health Aff (Millwood) , vol.32 , pp. 1433-1439
    • Lanthier, M.1    Miller, K.L.2    Nardinelli, C.3    Woodcock, J.4
  • 18
    • 84947259792 scopus 로고    scopus 로고
    • Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study
    • 18 Kesselheim, A.S., Wang, B., Franklin, J.M., Darrow, J.J., Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study. BMJ, 351, 2015, h4633.
    • (2015) BMJ , vol.351 , pp. h4633
    • Kesselheim, A.S.1    Wang, B.2    Franklin, J.M.3    Darrow, J.J.4
  • 19
    • 84905495729 scopus 로고    scopus 로고
    • The discovery of first-in-class drugs: origins and evolution
    • 19 Eder, J., Sedrani, R., Wiesmann, C., The discovery of first-in-class drugs: origins and evolution. Nat Rev Drug Discov 13 (2014), 577–587.
    • (2014) Nat Rev Drug Discov , vol.13 , pp. 577-587
    • Eder, J.1    Sedrani, R.2    Wiesmann, C.3
  • 20
    • 0034687597 scopus 로고    scopus 로고
    • Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations: main results of the GUARDIAN trial
    • 20 Théroux, P., Chaitman, B.R., Danchin, N., et al. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations: main results of the GUARDIAN trial. Circulation 102 (2000), 3032–3038.
    • (2000) Circulation , vol.102 , pp. 3032-3038
    • Théroux, P.1    Chaitman, B.R.2    Danchin, N.3
  • 21
    • 0043166526 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease
    • 21 Topol, E.J., Easton, D., Harrington, R.A., et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 108 (2003), 399–406.
    • (2003) Circulation , vol.108 , pp. 399-406
    • Topol, E.J.1    Easton, D.2    Harrington, R.A.3
  • 22
    • 37549062578 scopus 로고    scopus 로고
    • A randomised trial of a pre-synaptic stimulator of DA2-dopaminergic and alpha2-adrenergic receptors on morbidity and mortality in patients with heart failure
    • 22 Torp-Pedersen, C., Køber, L., Carlsen, J.E., et al. A randomised trial of a pre-synaptic stimulator of DA2-dopaminergic and alpha2-adrenergic receptors on morbidity and mortality in patients with heart failure. Eur J Heart Fail 10 (2008), 89–95.
    • (2008) Eur J Heart Fail , vol.10 , pp. 89-95
    • Torp-Pedersen, C.1    Køber, L.2    Carlsen, J.E.3
  • 23
    • 36348975228 scopus 로고    scopus 로고
    • Effects of torcetrapib in patients at high risk for coronary events
    • 23 Barter, P.J., Caulfield, M., Eriksson, M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007), 2109–2122.
    • (2007) N Engl J Med , vol.357 , pp. 2109-2122
    • Barter, P.J.1    Caulfield, M.2    Eriksson, M.3
  • 24
    • 84944937913 scopus 로고    scopus 로고
    • Reducing LDL with PCSK9 inhibitors—the clinical benefit of lipid drugs
    • 24 Everett, B.M., Smith, R.J., Hiatt, W.R., Reducing LDL with PCSK9 inhibitors—the clinical benefit of lipid drugs. N Engl J Med 373 (2015), 1588–1591.
    • (2015) N Engl J Med , vol.373 , pp. 1588-1591
    • Everett, B.M.1    Smith, R.J.2    Hiatt, W.R.3
  • 25
    • 84907087561 scopus 로고    scopus 로고
    • Angiotensin-neprilysin inhibition versus enalapril in heart failure
    • 25 McMurray, J.J., Packer, M., Desai, A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
    • (2014) N Engl J Med , vol.371 , pp. 993-1004
    • McMurray, J.J.1    Packer, M.2    Desai, A.S.3
  • 26
    • 0037417807 scopus 로고    scopus 로고
    • The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation
    • 26 Seidah, N.G., Benjannet, S., Wickham, L., et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 100 (2003), 928–933.
    • (2003) Proc Natl Acad Sci U S A , vol.100 , pp. 928-933
    • Seidah, N.G.1    Benjannet, S.2    Wickham, L.3
  • 27
    • 0037603589 scopus 로고    scopus 로고
    • Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
    • 27 Abifadel, M., Varret, M., Rabès, J.P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34 (2003), 154–156.
    • (2003) Nat Genet , vol.34 , pp. 154-156
    • Abifadel, M.1    Varret, M.2    Rabès, J.P.3
  • 28
    • 13944265645 scopus 로고    scopus 로고
    • Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
    • 28 Cohen, J., Pertsemlidis, A., Kotowski, I.K., Graham, R., Garcia, C.K., Hobbs, H.H., Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 37 (2005), 161–165.
    • (2005) Nat Genet , vol.37 , pp. 161-165
    • Cohen, J.1    Pertsemlidis, A.2    Kotowski, I.K.3    Graham, R.4    Garcia, C.K.5    Hobbs, H.H.6
  • 29
    • 33645103550 scopus 로고    scopus 로고
    • Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
    • 29 Cohen, J., Boerwinkle, E., Mosley, T.H. Jr., Hobbs, H.H., Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354 (2006), 1264–1272.
    • (2006) N Engl J Med , vol.354 , pp. 1264-1272
    • Cohen, J.1    Boerwinkle, E.2    Mosley, T.H.3    Hobbs, H.H.4
  • 30
    • 17244377696 scopus 로고    scopus 로고
    • Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
    • 30 Rashid, S., Curtis, D.E., Garuti, R., et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A 102 (2005), 5374–5379.
    • (2005) Proc Natl Acad Sci U S A , vol.102 , pp. 5374-5379
    • Rashid, S.1    Curtis, D.E.2    Garuti, R.3
  • 31
    • 84876260798 scopus 로고    scopus 로고
    • Genetics: a gene of rare effect
    • 31 Hall, S.S., Genetics: a gene of rare effect. Nature 496 (2013), 152–155.
    • (2013) Nature , vol.496 , pp. 152-155
    • Hall, S.S.1
  • 32
    • 84858638369 scopus 로고    scopus 로고
    • Effect of a monoclonal antibody to PCSK9 on LDL cholesterol
    • 32 Stein, E.A., Mellis, S., Yancopoulos, G.D., et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 366 (2012), 1108–1118.
    • (2012) N Engl J Med , vol.366 , pp. 1108-1118
    • Stein, E.A.1    Mellis, S.2    Yancopoulos, G.D.3
  • 33
    • 50149101511 scopus 로고    scopus 로고
    • Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
    • 33 Frank-Kamenetsky, M., Grefhorst, A., Anderson, N.N., et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A 105 (2008), 11915–11920.
    • (2008) Proc Natl Acad Sci U S A , vol.105 , pp. 11915-11920
    • Frank-Kamenetsky, M.1    Grefhorst, A.2    Anderson, N.N.3
  • 34
    • 84892741671 scopus 로고    scopus 로고
    • Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
    • 34 Fitzgerald, K., Frank-Kamenetsky, M., Shulga-Morskaya, S., et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383 (2014), 60–68.
    • (2014) Lancet , vol.383 , pp. 60-68
    • Fitzgerald, K.1    Frank-Kamenetsky, M.2    Shulga-Morskaya, S.3
  • 35
    • 84944097535 scopus 로고    scopus 로고
    • A cholesterol-lowering VLP vaccine that targets PCSK9
    • 35 Crossey, E., Amar, M.J., Sampson, M., et al. A cholesterol-lowering VLP vaccine that targets PCSK9. Vaccine 33 (2015), 5747–5755.
    • (2015) Vaccine , vol.33 , pp. 5747-5755
    • Crossey, E.1    Amar, M.J.2    Sampson, M.3
  • 36
    • 84959568573 scopus 로고    scopus 로고
    • Tribulations of recent cardiology trials, the audacity of hope, and HOPE-3
    • 36 Waters, D.D., Chau, K.H., Tribulations of recent cardiology trials, the audacity of hope, and HOPE-3. Can J Cardiol 32 (2016), 275–277.
    • (2016) Can J Cardiol , vol.32 , pp. 275-277
    • Waters, D.D.1    Chau, K.H.2
  • 37
    • 84926288672 scopus 로고    scopus 로고
    • Accessibility of trial reports for drugs stalling in development: a systematic assessment of registered trials
    • 37 Hakala, A., Kimmelman, J., Carlisle, B., Freeman, G., Fergusson, D., Accessibility of trial reports for drugs stalling in development: a systematic assessment of registered trials. BMJ, 350, 2015, h1116.
    • (2015) BMJ , vol.350 , pp. h1116
    • Hakala, A.1    Kimmelman, J.2    Carlisle, B.3    Freeman, G.4    Fergusson, D.5
  • 38
    • 84921781584 scopus 로고    scopus 로고
    • Sharing and reporting the results of clinical trials
    • 38 Hudson, K.L., Collins, F.S., Sharing and reporting the results of clinical trials. JAMA 313 (2015), 355–356.
    • (2015) JAMA , vol.313 , pp. 355-356
    • Hudson, K.L.1    Collins, F.S.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.